Most of the time exclusions don’t harm patients, according to experts. In some cases, they can even be beneficial, if patients are forced to switch to a drug that ends up working better for them.

Second, “this only applies for a highly select group of patients with dMMR/MSI tumors. It is critical that this biomarker be checked before immunotherapy is considered, as this type of treatment ...